The following link shows the commercial potential of PCSK9 inhibitors, with FDA-approved injectable drugs Repatha and Praluent expected to each generate sales of $1 Billion per year by 2020.
https://www.drugs.com/slideshow/pcsk9-inhibitors-a-new-option-in-cholesterol-treatment-1166
No one has been able to produce an oral drug that effectively binds to PCSK9 - until now.
PCSK9 has been validated as a cholesterol-lowering target, so how much might an oral inhibitor be worth to Big Pharma? I think I've said this before, but it is worth repeating: a Licence deal for NYX-330 would be worth about $5.00 per NOX share for each $1 Billion Big Pharma is willing to pay.
Nyrada is a hidden gem that is not reflected at all in the NOX share price, in my view.
Add to My Watchlist
What is My Watchlist?
